Novavax sees weak Covid vaccine sales
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi (SASY.PA), opens new tab.
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...
The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 ...
Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
(MENAFN- Live Mint) (Bloomberg) -- Novavax Inc. shares fell as much as 24% after US regulators placed a hold on the company's experimental influenza and COVID-19 combination vaccines because a ...
Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...
Hosted on MSN1d
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call TranscriptWe continue to work closely with our partner to enable a seamless ... immunologic comparisons to establish non-inferiority ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback